Displaying drugs 1151 - 1175 of 1181 in total
Brilacidin
Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.
Investigational
Temafloxacin
Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Withdrawn
IRX-5183
Investigational
Difloxacin
Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration. However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.
Vet approved
JNJ-41443532
JNJ-41443532 has been used in trials studying the basic science and treatment of Diabetes Mellitus, Type 2.
Investigational
Alisertib
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
Investigational
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
AVE-2865
Experimental
LCL-161
LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Investigational
osgemcitabine palabenamide
NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Investigational
BIA
Experimental
Emricasan
Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
Investigational
PCO-371
PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).
Investigational
Saprisartan
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism .
Experimental
CP-320626
Experimental
ABT-639
ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).
Investigational
Mdl 101,146
Experimental
AV-412
Investigational
Z-Val-Ala-Asp fluoromethyl ketone
Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.
Experimental
RU90395
Experimental
Displaying drugs 1151 - 1175 of 1181 in total